Colloidal gold immunochromatography test paper for combined diagnosis of COVID-19 and mycoplasma pneumoniae and preparation method thereof

A COVID-19, immunochromatographic detection technology, applied in the field of immunodiagnosis, can solve the problem of mycoplasma pneumonia chest X-ray examination is not characteristic, unable to make a diagnosis and other problems

Inactive Publication Date: 2020-07-17
HANGZHOU ALLTEST BIOTECH
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The clinical manifestations and chest X-ray examination of mycoplasma pneumonia are not characteri

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Colloidal gold immunochromatography test paper for combined diagnosis of COVID-19 and mycoplasma pneumoniae and preparation method thereof
  • Colloidal gold immunochromatography test paper for combined diagnosis of COVID-19 and mycoplasma pneumoniae and preparation method thereof
  • Colloidal gold immunochromatography test paper for combined diagnosis of COVID-19 and mycoplasma pneumoniae and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0055] Example 1

[0056] The IgM-coated mouse anti-human IgM antibody concentration of the test line is 0.1 mg / ml, and the concentration of the mouse anti-human IgG antibody coated with the test line IgG is 0.1 mg / ml; the quality control line C 4 coated The concentration of goat anti-mouse IgG antibody is 0.5 mg / ml. The colloidal gold conjugate treatment pad 2 is coated with the neocoronavirus N protein recombinant antigen-colloidal gold conjugate, the neocoronavirus N protein recombinant antigen-colloidal gold conjugate has a diameter of 40nm-100nm, and the neocoronavirus recombinant antigen The concentration is 1mg / ml.

[0057] In the preparation method of the colloidal gold immunochromatographic test paper for the joint diagnosis of COVID-19 and Mycoplasma pneumoniae, the A test paper specifically includes the following steps:

[0058] A) Preparation of test line T and quality control line C: Dilute the mouse anti-human IgM, mouse anti-human IgG, and goat anti-mouse IgG antibod...

Example Embodiment

[0067] Example 2

[0068] The difference from Example 1 is that the concentration of mouse anti-human IgM antibody coated with IgM of the detection line is 0.4 mg / ml, and the concentration of mouse anti-human IgG antibody coated with IgG of the detection line is 0.3 mg / ml; The concentration of goat anti-mouse IgG antibody coated with quality control line C 4 was 0.8 mg / ml. The colloidal gold conjugate treatment pad 2 is coated with the neocoronavirus N protein recombinant antigen-colloidal gold conjugate, the neocoronavirus N protein recombinant antigen-colloidal gold conjugate has a diameter of 40nm-100nm, and the neocoronavirus recombinant antigen The concentration is 3mg / ml.

[0069] In the preparation method of the colloidal gold immunochromatographic test paper for the joint diagnosis of COVID-19 and Mycoplasma pneumoniae, the A test paper specifically includes the following steps:

[0070] A) Preparation of test line T and quality control line C: Dilute the mouse anti-human I...

Example Embodiment

[0079] Example 3

[0080] The difference from Example 1 is that the concentration of mouse anti-human IgM antibody coated with IgM of the detection line is 1.0 mg / ml, and the concentration of mouse anti-human IgG antibody coated with IgG of the detection line is 1.0 mg / ml; The concentration of goat anti-mouse IgG antibody coated with quality control line C 4 was 1.2 mg / ml. The colloidal gold conjugate treatment pad 2 is coated with the neocoronavirus N protein recombinant antigen-colloidal gold conjugate, the neocoronavirus N protein recombinant antigen-colloidal gold conjugate has a diameter of 40nm-100nm, and the neocoronavirus recombinant antigen The concentration is 5mg / ml.

[0081] In the preparation method of the colloidal gold immunochromatographic test paper for the joint diagnosis of COVID-19 and Mycoplasma pneumoniae, the A test paper specifically includes the following steps:

[0082] A) Preparation of test line T and quality control line C: Dilute mouse anti-human IgM, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of immunodiagnosis, and discloses colloidal gold immunochromatography test paper for combined diagnosis of COVID-19 and mycoplasma pneumoniae aiming at theblank problem of COVID-19 and mycoplasma pneumoniae antibody detection in the prior art, which specifically comprises the following preparation steps: 1) preparing a detection line T and a quality control line C; 2) preparing a colloidal gold conjugate treatment pad; and 3) preparation of test paper: sequentially connecting and assembling the water absorption pad, the sample pad, the colloidal gold conjugate treatment pad, the antibody-coated modified nitrocellulose membrane and the PVC bottom plate to obtain a finished product. The prepared test paper can accurately detect whether a person has 2019-nCoV and mycoplasma pneumonia or not, is short in detection period, simple in detection process and portable in equipment, adopts an antibody antigen detection mode as the Antigen has no latent period, and the invention is visual and accurate in result display and high in specificity, can diagnose infection of new crowns and pulmonary branches at different time, and is high in detection efficiency.

Description

technical field [0001] The invention relates to the technical field of immunodiagnosis, in particular to a colloidal gold immunochromatographic test paper for combined diagnosis of COVID-19 and Mycoplasma pneumoniae. Background technique [0002] Acute respiratory diseases (ARD) account for a large proportion of all acute morbidity and mortality worldwide, with acute viral respiratory infections being the leading cause (approximately 80%). Major viral pathogens include influenza virus, respiratory disease syncytial virus (RSV), coronavirus, adenovirus and rhinovirus, and the combined global mortality rate of influenza and RSV alone reaches 300,000 deaths per year in children under 5 years of age . [0003] Novel coronavirus-infected pneumonia is an acute infectious pneumonia whose pathogen is a new type of coronavirus not previously found in humans, namely 2019-nCoV (novel coronavirus). The initial symptoms of patients are mostly fever, fatigue and dry cough, and gradually...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/569G01N33/558G01N33/543
CPCG01N33/56983G01N33/56933G01N33/54313G01N33/558G01N2333/165G01N2333/30
Inventor 陈金树张芳陆维克高飞彭通李红玲吴晓诚
Owner HANGZHOU ALLTEST BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap